Clinical Trial Update: Efficacy and Toxicity of Bepotastine 1,5% PF vs Olopatadine 0,2% With BAK on Allergic Conjunctivitis Treatment [Phase 4]

View source ↗

Summary

Phase 4 trial comparing bepotastine 1.5% preservative-free formulation versus olopatadine 0.2% with benzalkonium chloride for allergic conjunctivitis; completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis

Drugs mentioned

• Olopatadine 0.2% (olopatadine hydrochloride)
• bepotastine 1.5% preservative-free formulation (bepotastine)

Snippet

Sponsor: Laboratorios Poen | Conditions: Allergic Conjunctivitis | Phase 4 | Status: COMPLETED